
GeoVax Corporate Overview

October 2026

Nasdaq: GOVX

Forward Looking Statements



Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.

Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Addressing Critical Medical Needs with Near-term Value Creation

GEO-MVA

Pivotal Phase 3 **$2B+**

Mpox & Smallpox

A late-stage MVA vaccine program positioned to address preparedness and supply resilience.

Hemorrhagic Fever Viruses

IND-Enabling **$3B+**

Zaire • Sudan • Marburg

A differentiated MVA-based preparedness portfolio with collaboration and development potential.

Gedeptin®

Phase 2 **$15B+**

Solid Tumor Therapy

Clinical-stage oncology program providing meaningful portfolio and partnering optionality.

Strong IP estate • 55 patents across 13 families

GeoVax®

Upcoming Clinical Catalysts

Program			Milestones
GEO-MVA (mpox/smallpox vaccine)	**First U.S.-Sourced** U.S.-sourced MVA vaccine against Mpox & Smallpox; will expand global supply in a current market with significant unmet demand	**Expedited Development Path** Ph 1 and Ph 2 trials waived by EMA; only non-inferiority of immune comparison between GEO-MVA and MVA-BN (current approved MVA-vaccine) required for licensing	**Pivotal Ph 3 trial commencing Dec '26; Rapid enrollment & completion w/in 3 months; data readout mid-2027**
Gedeptin® (solid tumor therapy)	**Tumor Agnostic** Targeting multiple solid-tumor indications	**Enhancing Cancer Therapy** Combination of Gedeptin® and ICIs (i.e., Keytruda®) will enhance tumor therapies	**Ph 2 trial in 1st line head & neck cancer (Gedeptin® + Keytruda®) initiation targeted for H2'27**

Capital Strategy

Non-dilutive funding (BARDA, HHS, DoD, CEPI)

Strategic partnerships & collaborations

Reduced dependency on equity-sourced capital post-Ph 3 (GEO-MVA

GeoVax Investment Thesis

- **Near-term clinical/regulatory catalysts**
- **Structural monopoly break**
  - Single global MVA-vaccine supplier (non-U.S.) → GEO-MVA as U.S. sovereign alternative
  - National Security Asset: Only U.S.-based, scalable MVA manufacturing platform addressing a recognized biodefense and pandemic preparedness gap
- **De-risked platform with multi-program leverage**
- **Clear government & stockpile demand vectors**
- **Multiple partnering and collaboration paths → non-dilutive capital**
- **Pipeline optionality in demand area (oncology)**

GEO-MVA
(Mpox/smallpox vaccine)

De-risked, Expedited Vaccine Development

Addressing Significant Unmet Market Supply Need

Nasdaq: GOVX

GeoVax®

MVA: Modified Vaccinia Ankara

MVA is the vaccine that allowed smallpox to be eradicated worldwide

The only mpox/smallpox vaccine that is safe in all patient populations
(pregnant women; children; immunocompromised patients)

Single supplier (monopoly) worldwide: Bavarian-Nordic (MVA-BN)

- Limited supply capability – can't meet global demand
- 2025 sales of MVA-BN: $500 Million USD
- 2025 unmet demand of MVA-vaccine: ~ 15 million doses → ~$1.3 Billion USD

GEO-MVA is "essentially identical" to MVA-BN

GeoVax®

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

Confirms Single Phase 3 Immuno-Bridging Trial Sufficient to Evaluate Efficacy and to Support a Marketing Authorization Application (MAA) For Vaccination against Mpox and Smallpox

ATLANTA, GA – June 16, 2025 – *GeoVax Labs, Inc.* (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today announced that it has received positive Scientific Advice (SA) from the European Medicines Agency (EMA) for GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine for the prevention of Mpox and smallpox. The SA supports the suitability of GeoVax's clinical and nonclinical development strategy. This feedback from EMA provides clear regulatory alignment and enables an efficient pathway toward potential approval, eliminating multiple development steps commonly required for vaccines.

The EMA's Committee for Medicinal Products for Human Use (CHMP) confirmed the adequacy of GeoVax's proposed non-clinical immuno-bridging and toxicity studies to support progression to a Phase 3 study and MAA, assuming no unexpected findings occur. They **also confirmed Phase 1 and Phase 2 trials could be omitted and that a single, robustly designed Phase 3 immuno-bridging trial against the approved MVA vaccine (Imvanex), if successful, would be sufficient to support an MAA for GEO-MVA via the centralized procedure.** The CHMP also agreed with the Company's proposed immunogenicity endpoints in order to demonstrate non-inferiority. GeoVax believes this guidance represents a potentially significant acceleration in the regulatory approval timeline.

One Commercial Supplier → Significant Unmet Demand (2025)

Region / Organization	Estimated Additional Need*
Africa CDC	10M doses
European Preparedness Programs	3M doses
Global Health Agencies (Gavi / UNICEF, etc.)	2M doses
Total Unmet Demand	**15M doses = ~$1.3B**

Vaccine Sales	2025 Est. Market ($ USD)*
Current Vaccine Procurement	$0.7B
Unfulfilled MVA Demand	$1.3B
Total Current Demand	**$2.0B**

**Source: global procurement data and outbreak-driven demand estimates*

GEO-MVA Positions GeoVax to Expand MVA-vaccine Supply in a Constrained Market

Current Market Is Highly Concentrated

Vaccine	Supplier	Platform	Est. 2025 Sales	Key Limitation
MVA-BN	Bavarian Nordic	Non-replicating MVA	~$500M	Capacity constrained
ACAM2000®	Emergent	Replicating vaccinia	~$150M	Contraindicated in various patients
LC16m8	KM Biologics	Attenuated vaccinia	~$50M	Contraindicated in various patients

~$700M current global procurement market

Significant Unmet Demand Exists

15M doses ($1.3B) of unmet global demand driven by:

- Africa CDC procurement gap
- European stockpile expansion
- Global health agency demand (UNICEF / GAVI)

$1.3B in Unmet Demand: GEO-MVA is Positioned to Address

GEO-MVA Validation of EMA Approvability

Milestone	Timing	Status
Preclinical Toxicology (early submission in support of clinical start)	Q2 2026 - Q1 2027	On track
Clinical : Immune Bridging Trial (n=500; Completion: 8-12 weeks)	Q4 2026 - Q1 2027	CRO selected; sites identified
Regulatory	Q1 2026 - Q2 2027	Ongoing
Manufacturing to Process Lock	Q2 2027 - Q4 2027	Initiated
Immune Bridging Readout / Confirmation of Approvability	Mid-year 2027	

GEO-MVA Commercialization & Growth

Milestone	Timing	Status/Comments
Procurement Discussions	Q2 2027	Discussions Initiated
WHO EUL/EMA Expedited Approval Discussions	Q3 2027	Informal Discussions Initiated
Regulatory (including MAA rolling submission)	Q3 2027 - MAA	Planning Underway
Manufacturing to Process Validation	Q2 2027 - Q3 2027	Initiated
Safety Database (n=3,000) Study	Q3 2027 - Q1 2028	CRO selected; Planning Underway

Rapid, Capital-Efficient Path to Clinical Validation

500-Patient Immune-bridging Study with Mid-2027 Readout

- 500 participants (healthy adults; 250 in each cohort)
- Neutralizing antibody endpoints
- Direct comparison to MVA-BN
- Enrollment: 8-12 weeks
- Mid-2027 readout

Q4 2026 Start

↓

Rapid Enrollment

↓

Day 42 Readout

↓

EMA/WHO Pathway

↓

Procurement Eligibility

Why GEO-MVA Today

- **Unmet Market Opportunity**
  - Supply-constrained market with approximately $1.3 billion in unmet demand (2025)
  - Single commercial supplier of MVA-vaccine worldwide: Bavarian-Nordic (MVA-BN)
  - GEO-MVA expands the MVA supply, addressing growing preparedness demand

- **De-risked Development Program**
  - Proven MVA vaccine platform preferred for use across all patient populations, including immunocompromised individuals
  - GEO-MVA is considered **"essentially identical"** to MVA-BN by regulatory authorities
  - Expedited EMA regulatory pathway through a single 500-patient**, Phase 3** immune-bridging study vs. MVA-BN

- **Near-Term Value Creation**
  - Phase 3 initiation expected in Q4 2026
  - Mid-2027 pivotal data readout
  - Potential for expedited regulatory authorization/EUA, accelerating GEO-MVA for procurement opportunities


GEO-MVA - A De-Risked Development Program

Genetics	Manufacturing	Regulatory	Clinical
Shared MVA lineage	Similar MVA process	Expedited EMA immune bridging pathway	EMA Ph3 immune bridging pathway
100% Region of Interest (ROI) sequence identity	Same dose & route	Ph1 & Ph2 waived	500 patient design

Supporting Scientific Context

- Established MVA vaccine platform
- Known orthopox immune correlates
- Historical >95% seroconversion

Preclinical Immunogenicity: GEO-MVA vs MVA-BN



Neutralizing antibodies (PRNT assay)

GEO-MVA Investment Highlights

✓ Existing commercial market
✓ $1.3B unmet demand
✓ Expansion supplier opportunity
✓ Expedited regulatory pathway
✓ Mid-2027 value inflection
✓ Procurement-driven revenue model
✓ Experienced vaccine leadership team

Building the next global supplier of MVA vaccines.

Gedeptin®

- Directing Tumors to Synthesize Their Own Anti-tumor Agents
- Broadening the Activity of Checkpoint Blockade

Gedeptin®

- **Clinical Stage treatment for solid tumors**
- **Gene Directed Enzyme Prodrug Therapy (GDEPT)**
  - Gedeptin®: Ad5 vector coding for E. coli purine nucleoside phosphorylase (Ad/PNP)
  - Prodrug: fludarabine phosphate
- **Mono- and/or Combination (w/ Immune Checkpoint Inhibitor) therapy**
- **MoA does not require actively replicating tumor cells:**
  - ”solid-tumor agnostic”
- **GeoVax acquired**
  - Exclusive world-wide rights to all indications from PNP Therapeutics in 2021
  - Exclusive rights from Emory University for use in combination with ICIs in 2026

Gedeptin®: A Gene-Directed Enzyme Prodrug Therapy for Solid Tumors

Gedeptin® Platform

- Gene-directed enzyme prodrug therapy enabling localized tumor cell killing
- Intratumoral delivery minimizes systemic toxicity
- Applicable across multiple needle-accessible solid tumors

Clinical Validation

- Completed Ph 1 and Ph 1/2 studies in advanced head & neck cancer
- Demonstrated safety and evidence of tumor shrinkage
- Orphan Drug Designation granted in head & neck cancer

Mechanistic Differentiation

- Converts a systemically administered prodrug into a cytotoxic agent *within the tumor*
- Effective in refractory tumors with limited response to standard therapies
- Potential to modulate the tumor microenvironment
- Suitable for combination with standard oncology regimens, including checkpoint inhibitors
- Designed for partner-led development and commercialization

GeoVax®

Gedeptin® Mechanism of Action

Tumor-Targeted Gene Delivery
A therapeutic gene is delivered directly into tumor cells.
Localized, intratumoral administration

Enzyme Expressed Only in Tumor
Tumor cells begin producing a foreign enzyme not found in healthy tissue

Prodrug Activated Inside Tumor
A systemically administered prodrug is converted into a potent toxin only inside the tumor.

Cancer Cell Death + Bystander Effect
Activated drug kills treated cancer cells and neighboring tumor cells

- Tumor-Selective Activation only in gene-expressing tumor cells
- Platform-Agnostic Application across multiple solid tumors
- Human Clinical Ph1/2 evidence of tumor-killing activity
- Combination optionality with Immune Checkpoint Inhibitors

Tumor-selective gene therapy evaluated in solid tumors, with potential applicability across indications and in combination regimens

GeoVax®

Gedeptin® Current Status

- **PNP-001: Phase 1a Advanced Head and Neck Cancers (completed)**
  - Rosenthal et al, Annals of Oncology 26: 1481-1487 (2015)
  - FDA orphan drug status granted
- **PNP-002: Phase 1b/2a Advanced Head and Neck Cancers (completed)**
  - Colevas et al. JCO Oncology Advances 2(1), 2025
  - Partial trial funding from FDA Office of Orphan Products Development (E Sorscher/E Rosenthal)
- **PNP-003: Phase 2 1st line Head & Neck Cancer in conjunction with Keytruda® (planned)**

GeoVax®

Oncology – Next Steps

- **Advance Gedeptin® into Ph 2** in selected, needle-accessible solid tumors (initial focus: head & neck), leveraging orphan designation and prior safety/tumor-shrinkage data
- **Initiate combination strategy clinical development** pairing Gedeptin® with ICIs (i.e., Keytruda®) to enhance inhibitor response
- **Generate partner-ready translational data** (immune activation, tumor microenvironment modulation) to support pharma collaboration discussions
- **Pursue oncology development primarily through strategic partnerships**, minimizing internal capital deployment while retaining platform upside
- **Evaluate non-dilutive funding opportunities** (grants, academic collaborations, foundation support) to offset development costs

Oncology programs are being advanced to value-inflection points through partnerships, preserving upside while maintaining capital discipline

Addressing Critical Medical Needs with Multiple Paths to Value Creation

Late-stage vaccine opportunity • oncology optionality • pandemic-preparedness platform

GEO-MVA

Phase 3 **$2B+**

Mpox & Smallpox

A late-stage MVA vaccine program positioned to address preparedness and supply resilience.

Gedeptin®

Phase 2 **$15B+**

Solid Tumor Therapy

Clinical-stage oncology program providing meaningful portfolio and partnering optionality.

Hemorrhagic Fever Viruses

IND-Enabling **$3B+**

Zaire • Sudan • Marburg

A differentiated MVA-based preparedness portfolio with collaboration and development potential.

Global development & commercialization through collaborations and partnerships

Strong IP estate • 55 patents across 13 families

GeoVax®

Thank you!!

David Dodd, CEO

ddodd@geovax.com

www.geovax.com